FDA panel votes in favor of approving The Medicines Co's cangrelor in periprocedural thrombotic events
A committee of the US Food and Drug Administration has voted 9-2 in support of the approval of The Medicines Company’s (Nasdaq: MDCO) cangrelor as an adjunct to percutaneous coronary intervention to reduce the risk of periprocedural thrombotic events
This is further to recent news that the FDA is backing the approval of the same drug for preventing blood clots in angioplasty. Loretta Itri, executive vice president of The Medicines Company, said: “We look forward to continuing to work with the FDA in the coming weeks to bring this product to patients.”
The FDA will issue its final decision on the approval of cangrelor by June 23, while European regulators have already cleared the drug for marketing under the name Kengrexal.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze